Zalutumumab

Zalutumumab (pronounced za-loo-too-moo-mab) is a monoclonal antibody designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN). It was developed by Genmab, a Danish biotechnology company.

Etymology

The name "Zalutumumab" follows the INN naming convention for monoclonal antibodies. The "zu" prefix indicates its human origin, the "tum" stem refers to its tumor targeting, and the "mab" suffix identifies it as a monoclonal antibody.

Mechanism of Action

Zalutumumab works by targeting the EGFR, which is overexpressed in many types of cancer, including SCCHN. By binding to the EGFR, Zalutumumab inhibits the growth and proliferation of cancer cells.

Clinical Trials

Zalutumumab has undergone Phase I and II clinical trials for the treatment of SCCHN. However, a Phase III trial was halted in 2011 due to lack of efficacy.

Related Terms

• Monoclonal Antibody
• Squamous Cell Carcinoma
• Epidermal Growth Factor Receptor
• Clinical Trials

See Also

• List of Monoclonal Antibodies
• Cancer Treatment

External links

• Medical encyclopedia article on Zalutumumab
• Wikipedia's article - Zalutumumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski